Teva Pharmaceutical Industries (NYSE:TEVA) Shares Down 5.8% – Time to Sell?

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) shares traded down 5.8% on Thursday. The stock traded as low as $40.25 and last traded at $39.7680. 1,566,017 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 6,848,271 shares. The stock had previously closed at $42.23.

Key Headlines Impacting Teva Pharmaceutical Industries

Investors following TEVA have been watching these headlines:

  • Positive Sentiment: A blended fair-value estimate for Teva rose to $50.51 from $48.94, with commentary citing its growth strategy and products including Austedo, Uzedy and Ajovy. The estimate is not a company forecast, but it adds to the constructive analyst tone. Read article
  • Neutral Sentiment: CEO Richard Francis and other executives are scheduled to present at three healthcare investor conferences. The appearances could provide updates, but no new business developments were announced. Read announcement
  • Negative Sentiment: A notice from investor-law firm SueWallSt says it is investigating potential claims related to the decline following Hughes’s departure. This is an investigation notice, not a finding of wrongdoing, but it adds a potential legal overhang. Read notice

Analyst Ratings Changes

A number of analysts recently commented on the stock. Oppenheimer upped their price target on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 9th. TD Cowen upped their target price on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $54.00 price objective on shares of Teva Pharmaceutical Industries in a report on Tuesday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Fourteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $48.64.

View Our Latest Research Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Stock Performance

The company has a 50 day moving average of $40.60 and a two-hundred day moving average of $35.24. The company has a market capitalization of $45.71 billion, a PE ratio of 91.23, a PEG ratio of 3.69 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The business had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same period last year, the business earned $0.78 EPS. Teva Pharmaceutical Industries’s revenue was down 1.9% compared to the same quarter last year. As a group, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 46,000 shares of the company’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total value of $1,928,780.00. Following the completion of the sale, the insider directly owned 80,760 shares in the company, valued at $3,386,266.80. This represents a 36.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Roberto Mignone sold 367,600 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $39.06, for a total transaction of $14,358,456.00. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 715,945 shares of company stock worth $29,061,351. 0.54% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. grew its stake in Teva Pharmaceutical Industries by 1.3% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company’s stock valued at $1,561,120,000 after acquiring an additional 500,000 shares in the last quarter. Wellington Management Group LLP increased its position in Teva Pharmaceutical Industries by 5.8% during the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock valued at $259,899,000 after acquiring an additional 419,329 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Teva Pharmaceutical Industries by 20.0% during the 3rd quarter. Goldman Sachs Group Inc. now owns 7,355,669 shares of the company’s stock valued at $291,284,000 after purchasing an additional 1,226,429 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Teva Pharmaceutical Industries by 1.5% during the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock valued at $145,076,000 after buying an additional 72,880 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Teva Pharmaceutical Industries by 128.1% in the second quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock worth $103,538,000 after purchasing an additional 1,716,315 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Further Reading

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.